Merseburger AS - Search Results

1

SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.

Bamias A, Merseburger AS, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Calabrò F, Kramer M, de Velasco G, Zakopoulou R, Tzannis K, Sternberg CN. Bamias A, et al. Among authors: merseburger as. ESMO Open. 2021 Jun;6(3):100152. doi: 10.1016/j.esmoop.2021.100152. Epub 2021 May 10. ESMO Open. 2021. PMID: 33984672 Free PMC article. Clinical Trial.

2

An update on the medical therapy of advanced metastatic renal cell carcinoma.

Kruck S, Merseburger AS, Gakis G, Kramer MW, Stenzl A, Kuczyk MA. Kruck S, et al. Among authors: merseburger as. Scand J Urol Nephrol. 2008;42(6):501-6. doi: 10.1080/00365590802203983. Scand J Urol Nephrol. 2008. PMID: 18615363 Review.

3

Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update.

Kruck S, Kuczyk MA, Gakis G, Kramer MW, Stenzl A, Merseburger AS. Kruck S, et al. Among authors: merseburger as. Rev Recent Clin Trials. 2008 Sep;3(3):212-6. doi: 10.2174/157488708785700311. Rev Recent Clin Trials. 2008. PMID: 18782079 Review.

4

Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.

Kramer MW, Kuczyk MA, Hennenlotter J, Serth J, Schilling D, Stenzl A, Merseburger AS. Kramer MW, et al. Among authors: merseburger as. Oncol Rep. 2008 Dec;20(6):1403-8. Oncol Rep. 2008. PMID: 19020721

5

Present state of target therapy for disseminated renal cell carcinoma.

Waalkes S, Kramer M, Herrmann TR, Schrader AJ, Kuczyk MA, Merseburger AS. Waalkes S, et al. Among authors: merseburger as. Immunotherapy. 2010 May;2(3):393-8. doi: 10.2217/imt.10.14. Immunotherapy. 2010. PMID: 20635903 Review.

6

[Targeted therapy of urological tumours. Experimental field or established therapeutic approach?].

Kramer MW, Krege S, Peters I, Merseburger AS, Kuczyk MA. Kramer MW, et al. Among authors: merseburger as. Urologe A. 2010 Oct;49(10):1260-5. doi: 10.1007/s00120-010-2397-2. Urologe A. 2010. PMID: 20848076 Review. German.

7

Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer.

Waalkes S, Atschekzei F, Kramer MW, Hennenlotter J, Vetter G, Becker JU, Stenzl A, Merseburger AS, Schrader AJ, Kuczyk MA, Serth J. Waalkes S, et al. Among authors: merseburger as. BMC Cancer. 2010 Sep 22;10:503. doi: 10.1186/1471-2407-10-503. BMC Cancer. 2010. PMID: 20860816 Free PMC article.

8

Does male sex influence the prognosis of patients with renal cancer?

Waalkes S, Rott H, Herrmann TR, Wegener G, Kramer MW, Merseburger AS, Schrader M, Hofmann R, Kuczyk MA, Schrader AJ. Waalkes S, et al. Among authors: merseburger as. Onkologie. 2011;34(1-2):24-8. doi: 10.1159/000323379. Epub 2011 Jan 24. Onkologie. 2011. PMID: 21346381

9

Current evidence for transurethral laser therapy of non-muscle invasive bladder cancer.

Kramer MW, Bach T, Wolters M, Imkamp F, Gross AJ, Kuczyk MA, Merseburger AS, Herrmann TR. Kramer MW, et al. Among authors: merseburger as. World J Urol. 2011 Aug;29(4):433-42. doi: 10.1007/s00345-011-0680-5. Epub 2011 May 5. World J Urol. 2011. PMID: 21544662 Review.

10

Decreased galectin-8 is a strong marker for recurrence in urothelial carcinoma of the bladder.

Kramer MW, Waalkes S, Serth J, Hennenlotter J, Tezval H, Stenzl A, Kuczyk MA, Merseburger AS. Kramer MW, et al. Among authors: merseburger as. Urol Int. 2011;87(2):143-50. doi: 10.1159/000328439. Epub 2011 Jul 14. Urol Int. 2011. PMID: 21757871

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

425 results

Search Page